BG9418 (interferon beta-1a) ( DrugBank: Interferon beta-1a, Interferon beta )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
97	Ulcerative colitis	1

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00168714 (ClinicalTrials.gov)	February 2004	9/9/2005	Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)	Avonex Pregnancy Exposure Registry	Prenatal Exposure Delayed Effects;Multiple Sclerosis;Pregnancy	Drug: BG9418 (interferon beta-1a)	Biogen Idec	NULL	Completed	N/A	N/A	Female	329	N/A	United States

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00616434 (ClinicalTrials.gov)	May 2008	5/2/2008	A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Avonex® in Subjects With Moderate to Severe Ulcerative Colitis	Active Ulcerative Colitis	Drug: BG9418 (Interferon beta-1a);Drug: Placebo	Biogen	NULL	Completed	18 Years	65 Years	All	123	Phase 2	United States;Canada;Czech Republic;Hungary;Poland;Russian Federation;Slovakia